Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glenmark’s Coup: Gilead’s Riva Now CEO Of Spin-Out Innovation Firm

Executive Summary

Glenmark has snagged a top name in oncology from Gilead to lead its spin-out innovation business.

You may also be interested in...



Crunch Time For Glenmark’s US Innovation Arm, Founding CEO To Exit

Glenmark’s spin-out innovation arm, Ichnos, faces a crucial year of effort to partner out certain potential first-in-class therapeutics for autoimmune diseases and also to advance its oncology pipeline. Meanwhile, CEO and ex-Gilead executive Alessandro Riva is moving on.

Gilead’s New O’Day Regime Has New R&D Structure

After several staff departures, Gilead consolidates its research arm under CEO oversight, while welcoming another Roche/Genentech alum. 

Glenmark Has An Orphan Ahead of Innovation Capital Raising Plan

FDA orphan drug designation for Glenmark’s multiple myeloma candidate is seen as an important milestone ahead of its innovation spin out’s plans to raise capital in the US to fund pipeline development.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124861

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel